These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12185961)

  • 1. Therapeutic drug monitoring of tacrolimus: a moving matter.
    Manzanares C
    Therapie; 2002; 57(2):133-6. PubMed ID: 12185961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
    Jain AK; Venkataramanan R; Shapiro R; Scantlebury VP; Potdar S; Bonham CA; Ragni M; Fung JJ
    Liver Transpl; 2002 Sep; 8(9):841-5. PubMed ID: 12200788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients.
    Trotter JF; Osborne JC; Heller M; Christians U
    Aliment Pharmacol Ther; 2005 Jul; 22(1):37-44. PubMed ID: 15963078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.
    Martin P; Busuttil RW; Goldstein RM; Crippin JS; Klintmalm GB; Fitzsimmons WE; Uleman C
    Liver Transpl; 2004 Oct; 10(10):1258-62. PubMed ID: 15376310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian and time-dependent variability in tacrolimus pharmacokinetics.
    Park SI; Felipe CR; Pinheiro-Machado PG; Garcia R; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2007 Apr; 21(2):191-7. PubMed ID: 17391292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients.
    Lumlertgul D; Noppakun K; Rojanasthien N; Kanchanarattanakorn K; Jittikanont S; Manoyot A; Bunnachak D; Ophascharoensuk V
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S73-8. PubMed ID: 17044457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.
    Sánchez-Pérez B; Aranda Narváez JM; Santoyo Santoyo J; Fernández-Aguilar JL; Suárez Muñoz MA; González-Sánchez AJ; Pérez Daga JA; Ramírez Plaza CP; Carrasco Campos J; Jiménez Mazure C; Becerra Ortíz R
    Transplant Proc; 2008 Nov; 40(9):2994-6. PubMed ID: 19010171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients.
    Tector AJ; Fridell JA; Mangus RS; Shah A; Milgrom M; Kwo P; Chalasani N; Yoo H; Rouch D; Liangpunsakul S; Herring S; Lumeng L
    Liver Transpl; 2004 Mar; 10(3):404-7. PubMed ID: 15004768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: a pilot study.
    Guitard J; Sandres-Sauné K; Kamar N; Ribes D; Faguer S; Esposito L; Lavit M; Muscari F; Péron JM; Lavayssière L; Durand D; Rostaing L
    Transplant Proc; 2007 Oct; 39(8):2603-5. PubMed ID: 17954189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation.
    Guaraldi G; Cocchi S; Codeluppi M; Di Benedetto F; Bonora S; Pecorari M; Gennari W; Cautero N; Pinna AD; Gerunda GE; Esposito R
    Transplant Proc; 2005; 37(6):2609-10. PubMed ID: 16182761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First clinical experience with the new once-daily formulation of tacrolimus.
    First MR
    Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period.
    Blanchet B; Duvoux C; Costentin CE; Barrault C; Ghaleh B; Salvat A; Jouault H; Astier A; Tod M; Hulin A
    Ther Drug Monit; 2008 Aug; 30(4):412-8. PubMed ID: 18641556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C.
    Margarit C; Bilbao I; Castells L; Lopez I; Pou L; Allende E; Escartin A
    Transpl Int; 2005 Dec; 18(12):1336-45. PubMed ID: 16297052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation.
    Lee MN; Butani L
    Pediatr Transplant; 2007 Jun; 11(4):388-93. PubMed ID: 17493218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults.
    Park K; Kim YS; Kwon KI; Park MS; Lee YJ; Kim KH
    Clin Ther; 2007 Jan; 29(1):154-62. PubMed ID: 17379055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring.
    Ragette R; Kamler M; Weinreich G; Teschler H; Jakob H
    J Heart Lung Transplant; 2005 Sep; 24(9):1315-9. PubMed ID: 16143250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.